Traduction de «include the forward restructuring » (Néerlandais → Français) :

Q4 2007 results only include the Forward restructuring charge (USD 325 million after tax).
Les résultats du T4 2007 n’incluent que les charges de restructuration Forward (USD 325 millions après impôts).

Other Income & Expenses, net, fell to 2.1% of net sales from 8.0% in the 2007 quarter, which included a Forward restructuring charge of USD 307 million.
Le poste Autres produits et charges, nets, a chuté à 2,1% du chiffre d’affaires net contre 8,0% au quatrième trimestre 2007, qui comprenait des charges de restructuration Forward d’USD 307 millions.

The 2007 results included exceptional charges of approximately USD 1.0 billion (USD 590 million for a Corporate environmental provision increase and USD 444 million of Forward restructuring charges).
Ce projet libère des ressources pour investir dans l’innovation et l’expansion dans des marchés en forte croissance. Le résultat de 2007 comprenait des charges exceptionnelles d'USD 1,0 milliard environ (USD 590 millions pour l’augmentation de la provision environnementale de Corporate et USD 444 millions pour des charges de restructuration induites par Forward).

1 Operating and net income in 2007 include exceptional charges of USD 1 034 million (USD 788 million after tax) for a Corporate environmental provision increase (Q3: USD 590 million) and Forward restructuring (Q4: USD 444 million).
1 Le résultat opérationnel et le résultat net de 2007 comprennent des charges exceptionnelles d’USD 1 034 millions (USD 788 millions après impôts) pour l’augmentation de la provision environnementale de Corporate (T3: USD 590 millions) et pour les charges de restructuration Forward (T4: USD 444 millions).

1 Operating income in 2007 includes USD 1 034 million of exceptional charges (USD 590 million for a Corporate environmental provision increase and USD 444 million for Forward restructuring charges, of which Pharmaceuticals: USD 307 million, Consumer Health: USD 97 million and Corporate: USD 40 million).
pour une augmentation de la provision environnementale de Corporate et USD 444 millions pour charges de restructuration Forward, dont USD 307 millions à Pharmaceuticals, USD 97 millions à Consumer Health et USD 40 millions à Corporate).

Corporate Income & Expense, net Net expenses in 2007 included charges of USD 630 million for the environmental provision increase and Corporate-related Forward restructuring charges.
Produits/charges nets de Corporate Les dépenses nettes de 2007 comprenaient un montant d’USD 630 millions pour l’augmentation de la provision environnementale et charges de restructuration Forward liées à Corporate.

The 2007 quarter also included USD 40 million of Forward restructuring charges.
La période correspondante de 2007 comprenait également pour USD 40 millions de charges de restructuration Forward.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines.
DISCLOSURE NOTICE: The information contained in this release is as of December 12, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.